Results 41 to 50 of about 19,369 (169)

MEK inhibition causes BIM stabilization and increased sensitivity to BCL-2 family member inhibitors in RAS-MAPK-mutated neuroblastoma

Frontiers in Oncology, 2023
IntroductionMutations affecting the RAS-MAPK pathway occur frequently in relapsed neuroblastoma tumors and are associated with response to MEK inhibition in vitro.
Thomas F. Eleveld, Thomas F. Eleveld, Lindy Vernooij, Linda Schild, Bianca Koopmans, Lindy K. Alles, Marli E. Ebus, Rana Dandis, Harm van Tinteren, Huib N. Caron, Jan Koster, Max M. van Noesel, Godelieve A. M. Tytgat, Selma Eising, Rogier Versteeg, M. Emmy M. Dolman, M. Emmy M. Dolman, M. Emmy M. Dolman, Jan J. Molenaar, Jan J. Molenaar   +19 more
doaj   +1 more source

The 9th International RASopathies Symposium

American Journal of Medical Genetics Part A, EarlyView.
ABSTRACT The RASopathies are a group of congenital disorders with overlapping clinical manifestations that are caused by pathogenic germline or early somatic variants that result in the hyperactivation of the RAS/mitogen‐activated protein kinase (MAPK) signaling pathway.
Pau Castel, Lisa Schoyer, Beth Stronach, Raya Bogdanova, Anton M. Bennett, Jaishri Blakeley, Miriam Bornhorst, Tammy Bowers, Saskia M. Brachmann, Emma Burkitt‐Wright, Kathryn Chatfield, Alessandro De Luca, Khalil El‐Chammas, Abdul Elkadri, John E. Fortunato, Bruce D. Gelb, Anne Goriely, Karen Gripp, Kassidy Grover, Lindsay Homan, Kenneth A. Kern, Maija Kiuru, Charles (Chuck) Lawson, Yong‐Seok Lee, Frank McCormick, Gina Ney, Cristina Nuevo‐Tapioles, Sara Pardej, Elizabeth I. Pierpont, Julia Plank, Nancy Ratner, Katherine A. Rauen, J. Elliott Robinson, Les Rogers, Sarah E. Sheppard, Keir Shiels, David Stevenson, Dagmar Tiemens, Matthew Traylor, K. Nicole Weaver, Marielle Yohe, Tamar Green   +41 more
wiley   +1 more source

Impact of extended insurance coverage on survival outcomes among patients with metastatic colorectal cancer in Taiwan

British Journal of Clinical Pharmacology, EarlyView.
Aims Predetermined treatment duration limits (PTDLs) are often used by Taiwan's National Health Insurance Administration to contain healthcare costs, but they may compromise patient outcomes. Therefore, we studied Taiwan's 2017 extension of the bevacizumab PTDL from 24 to 36 weeks in metastatic colorectal cancer (mCRC) to evaluate whether prolonged ...
Wei‐Ming Huang, Chen‐Han Chueh, Chien‐Yu Tseng, Christopher N. Kaufmann, Earl J. Morris, Chiao‐En Wu, Yi‐Wen Tsai   +6 more
wiley   +1 more source

Pharmacokinetic Drug–Drug Interaction Potential of Oral Anticancer Drugs

Clinical Pharmacology &Therapeutics, EarlyView.
Drug–drug interaction (DDI) management is critical for safe and effective use of oral anticancer drugs (OADs). Our study objectives were to (i) compile clinically relevant pharmacokinetic (PK) DDI mechanisms for OADs and (ii) assess the prevalence of PK potential DDIs (PDDIs) in patients with advanced solid cancers.
Fatimah Alhurayri, Islam R. Younis, Shadia I. Jalal, Theodore F. Logan, Rohan Maniar, Steven M. Bray, Sara K. Quinney, Zeruesenay Desta, Todd C. Skaar, James E. Tisdale, Tyler Shugg   +10 more
wiley   +1 more source

Comment on: “Challenging the Odds: Long‐Term Survival in Pediatric Diffuse Midline Glioma With H3 K27M and BRAF V600 Co‐Mutations Treated With Upfront Radiotherapy and Targeted Therapy”

Pediatric Blood &Cancer, EarlyView.
Natália Dassi, Andrea Maria Cappellano
wiley   +1 more source

Precision therapies for genetic epilepsies in 2025: Promises and pitfalls

Epilepsia Open, EarlyView.
Abstract By targeting the underlying etiology, precision therapies offer an exciting paradigm shift to improve the stagnant outcomes of drug‐resistant epilepsies, including developmental and epileptic encephalopathies. Unlike conventional antiseizure medications (ASMs) which only treat the symptoms (seizures) but have no effect on the underlying ...
Shuyu Wang, Emilio Perucca, Samuel F. Berkovic, Piero Perucca   +3 more
wiley   +1 more source

Inhibition of MEK with trametinib enhances the efficacy of anti-PD-L1 inhibitor by regulating anti-tumor immunity in head and neck squamous cell carcinoma

OncoImmunology, 2019
Major histocompatibility complex (MHC) class I downregulation is the primary immune evasion mechanism associated with failure in anti-PD-1/PD-L1 blockade therapies for cancer.
Seong-Ho Kang, Bhumsuk Keam, Yong-Oon Ahn, Ha-Ram Park, Miso Kim, Tae Min Kim, Dong-Wan Kim, Dae Seog Heo   +7 more
doaj   +1 more source

Brain Metastases From Differentiated Thyroid Cancer in the Era of Targeted Therapies: A Multi‐Center Retrospective Cohort

Head &Neck, EarlyView.
ABSTRACT Background Brain metastases (BM) of differentiated thyroid carcinoma (DTC) are associated with unfavorable prognosis. This study evaluated BM management strategies and patients' outcomes. Methods A retrospective review of patients diagnosed with DTC and BM at Tel Aviv Sourasky and Rabin Medical Centers between 1985 and 2024. Clinical features,
Liyona Kampel, Shaun Edalati, Eyal Yosefof, Anton Warshavsky, Gilad Horowitz, Nidal Muhanna, Hagit Shoffel‐Havakuk, Eyal Robenshtok, Aron Popovtzer, Inbar Finkel   +9 more
wiley   +1 more source

A Phase 1/1B Trial of Pembrolizumab and Trametinib in Advanced NSCLC Enriched for KRAS Mutations

JTO Clinical and Research Reports
Introduction: MEK inhibition (MEKi) combined with programmed death ligand 1 inhibition (immune checkpoint inhibitor [ICI]) modulates the tumor immune microenvironment.
Jonathan W. Riess, MD, MS, Matthew S. Lara, BS, Guillaume Luxardi, PhD, Miguel Lopez de Rodas, MD, Michiko Shimoda, PhD, Karen Kelly, MD, Primo N. Lara, MD, Laurel Beckett, PhD, Arta Monjazeb, MD, PhD, Kurt A. Schalper, MD, PhD, Emanual Maverakis, MD, David R. Gandara, MD   +11 more
doaj   +1 more source

Impact of non‐genetic heterogeneity of BRAF‐mutant colon cancer organoids on growth kinetics, drug sensitivity and Wnt dynamics

International Journal of Cancer, EarlyView.
What's New? Patient‐derived organoids (PDOs) model tumor biology and drug response while preserving key tumor features, yet the impact of non‐genetic culture variables is poorly understood. This study examined the influence of organoid size, seeding density, and morphology on growth, drug sensitivity, and Wnt signaling in a colorectal cancer organoid ...
Viktoria Zieger, Ellen Woehr, Jasmin Traichel, Tilman Brummer, Roland Zengerle, Sabrina Kartmann, Stefan Zimmermann   +6 more
wiley   +1 more source